Kelly Lawrence W & Associates Inc. CA Sells 1,000 Shares of Pfizer Inc. (NYSE:PFE)

Kelly Lawrence W & Associates Inc. CA cut its holdings in Pfizer Inc. (NYSE:PFE) by 9.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,130 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Kelly Lawrence W & Associates Inc. CA’s holdings in Pfizer were worth $242,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of PFE. Vanguard Group Inc. increased its stake in shares of Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC raised its stake in Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares during the last quarter. Norges Bank bought a new stake in Pfizer in the fourth quarter worth $2,328,986,000. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group reduced their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.07.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.4 %

NYSE:PFE opened at $22.13 on Friday. The firm has a 50 day moving average of $24.88 and a 200 day moving average of $26.17. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market capitalization of $125.50 billion, a price-to-earnings ratio of 15.69, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.